Beam Therapeutics Stock (NASDAQ:BEAM)
Previous Close
$24.18
52W Range
$16.95 - $49.50
50D Avg
$26.07
200D Avg
$27.54
Market Cap
$1.92B
Avg Vol (3M)
$1.23M
Beta
1.85
Div Yield
-
BEAM Company Profile
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM Performance
Peer Comparison
Ticker | Company |
---|---|
SANA | Sana Biotechnology, Inc. |
DNA | Ginkgo Bioworks Holdings, Inc. |
CRSP | CRISPR Therapeutics AG |
VRTX | Vertex Pharmaceuticals Incorporated |
FATE | Fate Therapeutics, Inc. |
NTLA | Intellia Therapeutics, Inc. |
EDIT | Editas Medicine, Inc. |
PRME | Prime Medicine, Inc. |
VERV | Verve Therapeutics, Inc. |
CRBU | Caribou Biosciences, Inc. |